NEW
YORK, March 24, 2025 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or
the Company), a pioneer in the development of targeted
radiotherapies, today announced it has entered into an
agreement for the supply of Actinium-225 (Ac-225) with Eckert &
Ziegler. Under this agreement, Actinium Pharmaceuticals will have
access to Eckert & Ziegler's high-quality Actinium-225 to
further develop its lead product Actimab-A as well as additional
early and late-stage development candidates for both U.S. and
international clinical trials.
Targeted radiotherapies using Ac-225 have shown great promise in
the treatment of cancer. The radioisotope releases powerful alpha
particles with high energy and low penetration depth, enabling
precise targeting of tumor cells, including hard-to-reach
micrometastases, while minimizing effects on surrounding healthy
tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed
against CD33, a receptor overexpressed in patients with acute
myeloid leukemia (AML) and other myeloid indications.
Sandesh Seth, Chairman and CEO at
Actium Pharmaceuticals, Inc. commented: "We believe that targeted
radiation therapy with Actinium-225 is one of the most promising
approaches for treating patients with myeloid malignancies and
solid tumors. As we have highlighted recently, we are advancing our
lead targeted radiotherapy Actimab-A into a pivotal Phase 2/3 trial
for patients with relapsed or refractory acute myeloid leukemia and
in the frontline setting in a Phase 1 trial under our CRADA with
the NCI. Additionally, we have launched our Actimab-A solid tumor
program to combine with PD-1 checkpoint inhibitors KEYTRUDA and
OPDIVO for patients with head and neck squamous carcinoma and
non-small cell lung cancer in multiple trials. As a pioneer in the
development of target radiotherapies, we have aggressive plans to
expand our clinical pipeline to address indications with high unmet
needs. With this supply agreement with Eckert & Ziegler, we
will have access to reliable and constant supply of Ac-225 to
advance our product development both in the U.S. as well as
internationally."
"We are happy to contribute to the continuous expansion of
indications for Actinium-225, which is significantly being advanced
by Actinium Pharmaceuticals," explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler
SE. "The progress we have made in our Ac-225 project over the past
year marks only the start of our program to address the global
shortage of this vital radionuclide."
Eckert & Ziegler reliably supplies high-quality Gallium-68,
Lutetium-177, Yttrium-90, and Actinium-225 to leading
pharmaceutical companies, and research institutions worldwide. With
expertise in radioisotope production and global logistics, the
company is committed to continuously support the development and
delivery of innovative radiopharmaceuticals.
About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a
leading specialist in isotope-related components for nuclear
medicine and radiation therapy. The company offers a broad range of
services and products for the radiopharmaceutical industry, from
early development work to contract manufacturing and distribution.
Eckert & Ziegler shares (ISIN DE0005659700) are listed in the
TecDAX index of Deutsche Börse.
Contributing to saving lives.
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in the development of targeted
radiotherapies intended to meaningfully improve patient outcomes.
Actinium is advancing its lead product candidate Actimab-A, a CD33
targeting therapeutic, as potential backbone therapy in acute
myeloid leukemia (AML) and other myeloid malignancies leveraging
the mutation agnostic alpha-emitter radioisotope payload
Actinium-225 (Ac-225). Actimab-A has demonstrated potential
activity in relapsed and refractory acute myeloid leukemia (r/r
AML) patients in combination with the chemotherapy CLAG-M including
high rates of Complete Remissions (CR) and measurable residual
disease (MRD) negativity leading to improved survival outcomes and
is being advanced to a pivotal Phase 2/3 trial. In addition,
Actinium is engaged with the National Cancer Institute (NCI) under
the Cooperative Research and Development Agreement (CRADA) for
development of Actimab-A in AML and other myeloid malignancies. The
first clinical trial under the CRADA will evaluate the triplet
combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an
oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka
holdings company) a novel oral hypomethylating agent (HMA) in
frontline acute myeloid leukemia (AML) patients. Additionally,
Actinium is developing Actimab-A as a potential pan tumor therapy
in combination with PD-1 checkpoint inhibitors including
KEYTRUDA® and OPDIVO® by depleting myeloid
derived suppressor cells (MDSCs), which represents a potential
multi-billion-dollar addressable market. Iomab-ACT, Actinium's next
generation conditioning candidate, is being developed with the goal
of improving patient access and outcomes for potentially curative
cell and gene therapies. Iomab-B is an induction and conditioning
agent prior to bone marrow transplant in patients with r/r AML,
which Actinium is seeking a potential strategic partner for the
U.S. In addition, the company's R&D efforts are primarily
focused on advancing several preclinical programs for solid tumor
indications. Actinium holds 230 patents and patent applications
including several patents related to the manufacture of the isotope
Ac-225 in a cyclotron.
For more information, please
visit: https://www.actiniumpharma.com/
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Investors:
investorrelations@actiniumpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-supply-agreement-with-eckert--ziegler-for-ac-225-radioisotope-to-support-comprehensive-development-activities-302409600.html
SOURCE Actinium Pharmaceuticals, Inc.
